Infigratinib | Interleukin Related interleukin-related.com

Product Name :
Infigratinib

Search keywords :
Infigratinib

drugId :
null

Target Vo:
Fibroblast growth factor receptor 2

Target Vo Short Name :
FGFR2

Moa_Name:
Fibroblast growth factor receptor 2 antagonists

First Approval Country :
United States

First Approval Date Filter:
2021

Origin Company_Name :
Novartis Pharma Ag

Active Company_Name :
Alcami Carolinas Corporation

Active Indication_Name:
Achondroplasia

In Active Indication_Name:
Urinary Bladder Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 2 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Acetyl CoA Carboxylase 1 (ACC1) Antibody
Phospho-ULK1 (Ser556) Antibody
Pyruvate Dehydrogenase E1 beta subunit Antibody: Pyruvate Dehydrogenase E1 beta subunit Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 39 kDa, targeting to Pyruvate Dehydrogenase E1 beta subunit. It can be used for WB,IHC-P,FC,IP assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts